|
Cipla Ltd announced that its wholly owned step-down subsidiary Cipla USA Inc, and Amgen Inc reach a settlement on pending litigation in the US District Court for the District of Delaware in January 2019 involving generic cinacalcet hydrochloride tablets.
A formal stipulation of dismissal has been filed with the Court and is awaiting signature by the presiding Judge.
The resolution entitles Cipla and its affiliates to continue importing, marketing, and selling its generic cinacalcet hydrochloride tablets 30mg, 60mg and 90mg in the United States.
Cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis, for the treatment of hypercalcemia in adult patients with parathyroid carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.
|